September 2026
Zipalertinib Combined with Chemotherapy Enhances Survival for Lung Cancer Patients
The addition of zipalertinib to standard chemotherapy has been shown to significantly enhance progression-free survival in patients with advanced non-small cell lung cancer with specific…
Trastuzumab deruxtecan Outperforms Traditional Treatments in HER2-Mutant Lung Cancer
The phase 3 DESTINY-Lung04 trial revealed that trastuzumab deruxtecan significantly enhances progression-free survival in patients with advanced HER2-mutant lung cancer compared to traditional treatments. This…
Risvutatug Rezetecan Shows Promise in Improving Survival for Relapsed Small-Cell Lung Cancer
The Phase III ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly enhances overall survival in patients with relapsed small-cell lung cancer compared to topotecan. This trial's…
Atezolizumab Plus Chemotherapy Doubles Event-Free Survival in Lung Cancer Patients
The Phase III IMpower030 trial showed that patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) who received perioperative atezolizumab plus chemotherapy had a…
Platinum Chemotherapy Linked to Long-Term DNA Damage in Healthy Cells of Children
Recent research has shown that platinum chemotherapy, used to treat childhood cancer, can cause significant DNA damage in healthy cells, with potential long-term effects on…
Scientists Develop Cost-Effective and Stable Catalyst for Hydrogen Fuel Cells
Researchers from Southern Federal University and several Russian institutions have developed a five-metal alloy catalyst for fuel cells that is cheaper and more stable than…
Initial Catalyst Structure Influences Fuel-Cell Ink Development
Researchers from Kanazawa University, the University of Tokyo, and HORIBA, Ltd. have discovered that the initial structure of platinum-on-carbon catalyst particles significantly affects the development…